Improving Time-to-Treatment for Advanced Non-Small Cell Lung Cancer Patients Through Faster Single Gene EGFR Testing Using the Idylla™ EGFR Testing Platform

Overview

Journal Curr Oncol

Publisher MDPI

Specialty Oncology

Date 2022 Oct 27

PMID 36290901

Authors

Norbert Banyi

Deepu Alex

Curtis Hughesman

Kelly McNeil

Diana N Ionescu

Carmen Ma

Stephen Yip

Barbara Melosky

Affiliations

Soon will be listed here.

Abstract

Introduction: Patients with advanced-stage non-small cell lung cancer (NSCLC) may benefit from a short time-to-treatment (TTT). Predictive biomarker testing is performed prior to treatment, as recommended by various international expert consensus bodies. Genetic testing is more time-intensive than immunohistochemistry (IHC) and commonly contributes to prolonged TTT. For epidermal growth factor receptor-positive patients (EGFR+), further genetic testing may not be required due to the mutual exclusivity of actionable mutations.

Methods: The trial cohort (N = 238) received both BC Cancer NGS panel (Oncopanel) and Idylla EGFR testing. Data were also collected for a control cohort (N = 220) that received Oncopanel testing. For each patient, the time that the lab received the sample, the time taken to report the NGS and Idylla tests, the time of first treatment, and the final treatment regimen were recorded.

Results: A concordance frequency of 98.7% (232/235) was observed between the Idylla and NGS panel. The lab turnaround time (TAT) was faster for the Idylla test by an average of 12.4 days (N = 235, < 0.01). Overall, the average TTT in the trial cohort (N = 114) was 10.1 days faster ( < 0.05) than the control (N = 114), leading to a 25% reduction in TTT. For patients treated based on EGFR positivity, the mean TTT was 16.8 days faster ( < 0.05) in the trial cohort (N = 33) than the control cohort (N = 28), leading to a 48% reduction in TTT.

Conclusion: Using the Idylla EGFR test as part of the molecular testing repertoire in advanced-stage NSCLC patients could significantly reduce TTT.

Citing Articles

Reduced wait times for molecular-biomarker testing among patients with advanced lung cancer using parallel sample processing and closed-loop communication: the Continuous Oncopanel and ALK Status Tracking (COAST) Project.

Yeo S, Sun J, Zibrik K, Shaipanich T, Carolan H, Melosky B BMJ Open Qual. 2025; 14(1).

PMID: 39971592 PMC: 11840910. DOI: 10.1136/bmjoq-2024-003001.

Evaluation of the Idylla™ EGFR Mutation Test on formalin-fixed, paraffin-embedded tissue of human lung cancer.

Xu Y, Zhang L, Jia L, Ren M, Xue T, Bai Q J Thorac Dis. 2024; 16(1):40-50.

PMID: 38410581 PMC: 10894364. DOI: 10.21037/jtd-23-1293.

Clinical Evaluation of IDH Mutation Status in Formalin-Fixed Paraffin-Embedded Tissue in Gliomas.

Nelson E, Gubbiotti M, Carlin A, Nasrallah M, Van Deerlin V, Herlihy S Mol Diagn Ther. 2023; 27(3):371-381.

PMID: 36690887 PMC: 9870658. DOI: 10.1007/s40291-022-00638-7.

References

de Montpreville V, Ghigna M, Lacroix L, Lemoine A, Besse B, Mercier O . EGFR and KRAS molecular genotyping for pulmonary carcinomas: Feasibility of a simple and rapid technique implementable in any department of pathology. Pathol Res Pract. 2017; 213(7):793-798. DOI: 10.1016/j.prp.2017.03.011. View

Arcila M, Drilon A, Sylvester B, Lovly C, Borsu L, Reva B . MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking. Clin Cancer Res. 2014; 21(8):1935-43. PMC: 4401580. DOI: 10.1158/1078-0432.CCR-14-2124. View

Nan X, Xie C, Yu X, Liu J . EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer. Oncotarget. 2017; 8(43):75712-75726. PMC: 5650459. DOI: 10.18632/oncotarget.20095. View

Uchida T, Kaira K, Yamaguchi O, Mouri A, Shiono A, Miura Y . Different incidence of interstitial lung disease according to different kinds of EGFR-tyrosine kinase inhibitors administered immediately before and/or after anti-PD-1 antibodies in lung cancer. Thorac Cancer. 2019; 10(4):975-979. PMC: 6449223. DOI: 10.1111/1759-7714.13039. View

Delgado-Garcia M, Weynand B, Gomez-Izquierdo L, Hernandez M, Blanco A, Varela M . Clinical performance evaluation of the Idylla™ EGFR Mutation Test on formalin-fixed paraffin-embedded tissue of non-small cell lung cancer. BMC Cancer. 2020; 20(1):275. PMC: 7126408. DOI: 10.1186/s12885-020-6697-7. View

To K, Fong W, Cho W . Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies. Front Oncol. 2021; 11:635007. PMC: 8185359. DOI: 10.3389/fonc.2021.635007. View

Sharma S, Satapathy A, Aggarwal A, Dewan A, Jain E, Katara R . Comparison of epidermal growth factor receptor mutation detection turnaround times and concordance among real-time polymerase chain reaction, high-throughput next-generation sequencing and the Biocartis Idylla™ platforms in non-small cell lung.... Pathol Res Pract. 2021; 220:153394. DOI: 10.1016/j.prp.2021.153394. View

Midha A, Dearden S, McCormack R . EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015; 5(9):2892-911. PMC: 4633915. View

Graham R, Treece A, Lindeman N, Vasalos P, Shan M, Jennings L . Worldwide Frequency of Commonly Detected EGFR Mutations. Arch Pathol Lab Med. 2017; 142(2):163-167. DOI: 10.5858/arpa.2016-0579-CP. View

10.

Petiteau C, Robinet-Zimmermann G, Riot A, Dorbeau M, Richard N, Blanc-Fournier C . Contribution of the Idylla System to Improving the Therapeutic Care of Patients with NSCLC through Early Screening of Mutations. Curr Oncol. 2021; 28(6):4432-4445. PMC: 8628756. DOI: 10.3390/curroncol28060376. View

11.

Sung M, Tomasini P, Le L, Kamel-Reid S, Tsao M, Liu G . Effects of Ethnicity on Outcomes of Patients With Mutation-Positive NSCLC Treated With EGFR Tyrosine Kinase Inhibitors and Surgical Resection. JTO Clin Res Rep. 2022; 3(2):100259. PMC: 8790496. DOI: 10.1016/j.jtocrr.2021.100259. View

12.

. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008; 455(7216):1061-8. PMC: 2671642. DOI: 10.1038/nature07385. View

13.

Ciriello G, Cerami E, Sander C, Schultz N . Mutual exclusivity analysis identifies oncogenic network modules. Genome Res. 2011; 22(2):398-406. PMC: 3266046. DOI: 10.1101/gr.125567.111. View

14.

De Luca C, Gragnano G, Pisapia P, Vigliar E, Malapelle U, Bellevicine C . mutation detection on lung cancer cytological specimens by the novel fully automated PCR-based Idylla Mutation Assay. J Clin Pathol. 2016; 70(4):295-300. DOI: 10.1136/jclinpath-2016-203989. View

15.

Evrard S, Taranchon-Clermont E, Rouquette I, Murray S, Dintner S, Nam-Apostolopoulos Y . Multicenter Evaluation of the Fully Automated PCR-Based Idylla EGFR Mutation Assay on Formalin-Fixed, Paraffin-Embedded Tissue of Human Lung Cancer. J Mol Diagn. 2019; 21(6):1010-1024. DOI: 10.1016/j.jmoldx.2019.06.010. View

16.

Oshima Y, Tanimoto T, Yuji K, Tojo A . EGFR-TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non-Small Cell Lung Cancer. JAMA Oncol. 2018; 4(8):1112-1115. PMC: 5885195. DOI: 10.1001/jamaoncol.2017.4526. View

17.

Melosky B, Banerji S, Blais N, Chu Q, Juergens R, Leighl N . Canadian consensus: a new systemic treatment algorithm for advanced mutated non-small-cell lung cancer. Curr Oncol. 2020; 27(2):e146-e155. PMC: 7253730. DOI: 10.3747/co.27.6007. View

18.

Skoulidis F, Heymach J . Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. Nat Rev Cancer. 2019; 19(9):495-509. PMC: 7043073. DOI: 10.1038/s41568-019-0179-8. View

19.

Jung J, Kim H, Kim D, Park S, Ko A, Han J . Sequential Treatment with an Immune Checkpoint Inhibitor Followed by a Small-Molecule Targeted Agent Increases Drug-Induced Pneumonitis. Cancer Res Treat. 2020; 53(1):77-86. PMC: 7812016. DOI: 10.4143/crt.2020.543. View

20.

Mok T, Ladrera G, Srimuninnimit V, Sriuranpong V, Yu C, Thongprasert S . Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer. Lung Cancer. 2016; 98:1-8. DOI: 10.1016/j.lungcan.2016.04.023. View